Science Explorer Interactive view Map
Company · Austin · United States

Lumos Pharma (United States)

lumos-pharma.comROR OpenAlex
Research works
23
▲ 163% vs 2013–17
Citations
351
15.5 per fractional work
Top-10% rate
11.7%
record average 16.5%
Open access
47%
world 28%

Not ranked overall: Lumos Pharma (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 3.26× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 2.73× its world share, 0 worksImmunology and Micro…Neuroscience: 1.50× its world share, 0 worksNeuroscienceEngineering: 0.41× its world share, 0 worksEngineeringEnvironmental Science: 0.88× its world share, 0 worksEnvironmental ScienceHealth Professions: 0.48× its world share, 0 worksHealth ProfessionsMedicine: 3.32× its world share, 5 worksMedicinePsychology: 0.06× its world share, 0 worksPsychologySocial Sciences: 0.12× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.3×. Every wedge is a field page.

Which keywords describe research at Lumos Pharma (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Metabolism, Cancer, IGF-1, Insulin-like Growth Factors, Inflammation, Obesity, Cardiovascular Disease and Epidemiology.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 8 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 8 words, with their numbers
  1. Cancer3▲ 9.0×4 topics
  2. Metabolism3▲ 20×3 topics
  3. IGF-12▲ 224×1 topic
  4. Insulin-like Growth Factors2▲ 224×1 topic
  5. Inflammation2▲ 3.6×9 topics
  6. Cardiovascular Disease1▲ 5.2×10 topics
  7. Epidemiology1▲ 1.43×12 topics
  8. Obesity1▲ 7.7×9 topics

Which research topics does Lumos Pharma (United States) publish most on?

By volume in 2022–2025: Growth Hormone and Insulin-like Growth Factors, Diabetes and associated disorders, Childhood Cancer Survivors' Quality of Life and Glycosylation and Glycoproteins Research.

Growth Hormone and Insul…2Growth Hormone and Insulin-like Growth Factors: 2 fractional worksDiabetes and associated disorders: 0 fractional worksChildhood Cancer Survivors' Quality of Life: 0 fractional worksGlycosylation and Glycoproteins Research: 0 fractional worksThyroid Disorders and Treatments: 0 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksBirth, Development, and Health: 0 fractional worksPharmaceutical studies and practices: 0 fractional worksProtein purification and stability: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional works
Endocrinology, Diabetes and MetabolismGeneticsPediatrics, Perinatology and Child HealthMolecular Biology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Growth Hormone and Insulin-like Growth Factors Endocrinology, Diabetes and Metabolism 2 works
  2. 2 Diabetes and associated disorders Genetics 0 works
  3. 3 Childhood Cancer Survivors' Quality of Life Pediatrics, Perinatology and Child Health 0 works
  4. 4 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  5. 5 Thyroid Disorders and Treatments Endocrinology, Diabetes and Metabolism 0 works
  6. 6 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  7. 7 Birth, Development, and Health Pediatrics, Perinatology and Child Health 0 works
  8. 8 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 0 works
  9. 9 Protein purification and stability Molecular Biology 0 works
  10. 10 Cancer Immunotherapy and Biomarkers Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.4%not open52.6%

World: 28% of research is openly available.

with international co-authors31.9%domestic only68.1%

World: 19% is written across borders.

How has Lumos Pharma (United States)'s research output changed?

Output in 2018–2022 was 163% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Austin

All research institutions in Austin

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.